CR20140325A - Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- - Google Patents

Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-

Info

Publication number
CR20140325A
CR20140325A CR20140325A CR20140325A CR20140325A CR 20140325 A CR20140325 A CR 20140325A CR 20140325 A CR20140325 A CR 20140325A CR 20140325 A CR20140325 A CR 20140325A CR 20140325 A CR20140325 A CR 20140325A
Authority
CR
Costa Rica
Prior art keywords
morofolinyl
mogat
inhibitors
derivatives
new useful
Prior art date
Application number
CR20140325A
Other languages
English (en)
Inventor
Maria Rosario Gonzalez-Garcia
Maria Carmen Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48905712&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140325(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20140325A publication Critical patent/CR20140325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Abstract

La presente invención se refiere a compuestos de Fórmula I, o una sal farmacéutica de los mismos, métodos para tratar hipertrigliceridemia usando los compuestos; y a un proceso para preparar los compuestos. WO 2013/116065 A1.
CR20140325A 2012-01-31 2014-07-08 Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- CR20140325A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382037 2012-01-31
US201261617093P 2012-03-29 2012-03-29
EP12382433 2012-11-06

Publications (1)

Publication Number Publication Date
CR20140325A true CR20140325A (es) 2014-08-25

Family

ID=48905712

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140325A CR20140325A (es) 2012-01-31 2014-07-08 Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-

Country Status (24)

Country Link
US (1) US8993568B2 (es)
EP (1) EP2809661B1 (es)
JP (1) JP5852269B2 (es)
KR (1) KR20140107641A (es)
CN (1) CN104080777B (es)
AP (1) AP2014007793A0 (es)
AU (1) AU2013215549B2 (es)
BR (1) BR112014018712A8 (es)
CA (1) CA2859992A1 (es)
CL (1) CL2014001862A1 (es)
CO (1) CO7020914A2 (es)
CR (1) CR20140325A (es)
DO (1) DOP2014000177A (es)
EA (1) EA024182B1 (es)
ES (1) ES2571577T3 (es)
GT (1) GT201400169A (es)
HK (1) HK1199024A1 (es)
IL (1) IL233542A0 (es)
MX (1) MX2014008604A (es)
PE (1) PE20141789A1 (es)
PH (1) PH12014501712B1 (es)
SG (1) SG11201404508XA (es)
WO (1) WO2013116065A1 (es)
ZA (1) ZA201405227B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
JP2016501844A (ja) 2012-11-06 2016-01-21 イーライ リリー アンド カンパニー ＭｏＧＡＴ−２阻害剤として有用な新規のベンジルスルホンアミド化合物
EP3395798A4 (en) 2015-12-21 2019-07-17 Shionogi & Co., Ltd NON-AROMATIC HETEROCYCLIC DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US20220135577A1 (en) 2019-01-11 2022-05-05 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO2000006083A2 (en) 1998-07-31 2000-02-10 Eli Lilly And Company Sulfonamide derivatives
AU5233999A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Alkenyl sulphonamide derivatives
GB0408777D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
US8232282B2 (en) 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
MX2010006220A (es) * 2007-12-05 2010-08-17 Astrazeneca Ab Derivados de morfolina como agentes antiobesidad.
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2725949A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab New pyridine derivatives as leptin receptor modulator mimetics
WO2010095767A1 (en) 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
JP2016501844A (ja) 2012-11-06 2016-01-21 イーライ リリー アンド カンパニー ＭｏＧＡＴ−２阻害剤として有用な新規のベンジルスルホンアミド化合物

Also Published As

Publication number Publication date
IL233542A0 (en) 2014-08-31
DOP2014000177A (es) 2014-08-31
CN104080777B (zh) 2015-12-09
AU2013215549A1 (en) 2014-07-17
MX2014008604A (es) 2014-08-22
ZA201405227B (en) 2016-05-25
HK1199024A1 (zh) 2015-06-19
PH12014501712A1 (en) 2014-10-13
EP2809661B1 (en) 2016-04-06
EP2809661A1 (en) 2014-12-10
KR20140107641A (ko) 2014-09-04
EA024182B1 (ru) 2016-08-31
PE20141789A1 (es) 2014-11-19
CA2859992A1 (en) 2013-08-08
BR112014018712A2 (es) 2017-06-20
GT201400169A (es) 2015-08-27
JP2015504917A (ja) 2015-02-16
US8993568B2 (en) 2015-03-31
JP5852269B2 (ja) 2016-02-03
SG11201404508XA (en) 2014-10-30
CL2014001862A1 (es) 2014-11-14
AP2014007793A0 (en) 2014-07-31
ES2571577T3 (es) 2016-05-26
EA201491227A1 (ru) 2015-01-30
PH12014501712B1 (en) 2014-10-13
CO7020914A2 (es) 2014-08-11
AU2013215549B2 (en) 2015-09-03
US20150005305A1 (en) 2015-01-01
BR112014018712A8 (pt) 2017-07-11
CN104080777A (zh) 2014-10-01
WO2013116065A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
CY1118681T1 (el) Αναστολεις νεπριλυσινης
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
GT201400022A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
CR20150370A (es) Compuestos antivirales
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
MX2015007916A (es) Peri-carbinoles.
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
DOP2017000034A (es) Compuestos de imidazopiridazina
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
CR20140553A (es) Compuestos de fenoxietil piperidina
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA201590656A1 (ru) Азаиндолины
EA201590696A1 (ru) Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
AR098134A1 (es) Compuestos de urea
CR20140130A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos
EA201501177A1 (ru) Фармацевтические композиции
UY33973A (es) Métodos de tratamiento dirigido de degeneración lobular frontotemporal.